US64125C1099 - Common Stock
NASDAQ:NBIX (2/2/2023, 9:01:59 AM)-2 (-1.81%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-01 2022-11-01/bmo | Earnings (Next) | 02-09 2023-02-09 |
Ins Owners | 1.04% | Inst Owners | 93.3% |
Market Cap | 10.40B | Shares | 96.13M |
PE | 189.86 | Fwd PE | 28.81 |
Dividend Yield | N/A | Analysts | 77.65 |
IPO | 05-23 1996-05-23 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 900 full-time employees. The firm is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
NEUROCRINE BIOSCIENCES INC
12780 El Camino Real
San Diego CALIFORNIA 92130
P: 18586177600.0
CEO: Kevin C. Gorman
Employees: 900
Website: https://www.neurocrine.com/
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Investors are taking profits on this red-hot stock this week.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results...
Sharp Tesla price cuts and some notable earnings were in focus.
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
Here you can normally see the latest stock twits on NBIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: